Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Universe Pharmaceuticals Inc. is a specialty and generic pharmaceutical manufacturer operating in a highly competitive segment with significant pricing pressure. The company faces severe operational challenges evidenced by negative operating margins (-16.3%), declining revenues (-22.4% YoY), and negative cash flow generation, though recent improvements in net income growth (57.9% YoY) suggest potential cost restructuring progress. The stock trades at distressed valuations (0.1x P/S) following a 56.8% decline over the past year, reflecting investor concerns about business viability and execution risk.
The company manufactures and distributes generic and specialty pharmaceutical products, competing primarily on price in the generic segment and on formulation differentiation in specialty products. With 35.3% gross margins, the company operates in a commoditized environment with limited pricing power, typical of generic manufacturers facing biosimilar competition and regulatory pricing pressures. The negative operating margin indicates the company is currently unable to cover SG&A and R&D expenses from gross profit, suggesting either insufficient scale, operational inefficiencies, or unsustainable cost structure. Revenue generation depends on regulatory approvals (ANDA filings for generics), distribution relationships with pharmacy benefit managers and wholesalers, and manufacturing efficiency to maintain cost competitiveness.
ANDA (Abbreviated New Drug Application) approval announcements for new generic products, which expand addressable market
Quarterly revenue trends and gross margin performance, particularly stabilization or reversal of the 22.4% YoY decline
Operating expense management and path to positive operating cash flow, given current -$0.0B OCF
Generic drug pricing environment and competitive intensity in key therapeutic categories
Regulatory compliance issues or FDA warning letters that could disrupt manufacturing operations
Strategic partnerships, licensing agreements, or M&A activity given the distressed valuation
Intensifying generic drug pricing pressure from increased competition, pharmacy benefit manager consolidation, and potential government price controls or Medicare negotiation expansion
Regulatory compliance risk inherent to pharmaceutical manufacturing, where FDA enforcement actions, warning letters, or facility shutdowns can immediately halt revenue from affected products
Biosimilar competition eroding margins in specialty pharmaceutical segments as patents expire on biologic drugs
Supply chain concentration risk if the company relies on Chinese or Indian API suppliers facing geopolitical or quality control disruptions
Commoditization of generic product portfolio with limited differentiation, facing competition from larger generic manufacturers (Teva, Mylan/Viatris) with superior scale economics
Inability to invest in R&D or business development given negative cash flow, falling behind competitors in new product launches and ANDA pipeline development
Loss of key distribution relationships or formulary exclusions if pharmacy benefit managers consolidate purchasing with larger generic suppliers
Negative operating cash flow and free cash flow creating liquidity risk if the company cannot access capital markets or reverse operational trends within 12-18 months
Potential going concern risk if revenue decline continues and the company exhausts cash reserves, though 4.07x current ratio provides near-term buffer
Working capital inefficiency suggested by high current ratio potentially masking inventory obsolescence or uncollectible receivables that could require write-downs
Equity dilution risk if the company needs to raise capital at distressed valuations (0.1x P/S) to fund operations
low - Pharmaceutical demand is relatively inelastic and non-cyclical, as patients require medications regardless of economic conditions. However, the company's financial distress creates indirect cyclical sensitivity: in recessions, access to capital markets tightens, making refinancing or equity raises more difficult for cash-burning businesses. Generic drug utilization may actually increase during downturns as patients and insurers shift from branded to lower-cost alternatives, but pricing pressure intensifies as competitors fight for volume.
Rising interest rates create moderate negative pressure through two channels: (1) higher cost of capital for a cash-burning business that may need external financing, though current 0.16x debt/equity suggests minimal debt burden; (2) valuation multiple compression as discount rates increase, particularly impactful for unprofitable companies trading on forward earnings potential. The company's 4.07x current ratio provides liquidity buffer, but negative free cash flow means rate increases affect refinancing risk if working capital needs grow.
Moderate - While pharmaceutical demand is stable, the company's negative cash flow and operating losses create credit risk if it needs to access debt markets or renegotiate existing facilities. Tightening credit conditions (widening high-yield spreads) would increase financing costs and potentially limit access to capital needed for working capital or restructuring. The low 0.16x debt/equity suggests current debt burden is manageable, but credit availability matters for operational continuity given cash burn.
value/special situations - The stock trades at distressed valuations (0.1x P/S, 0.0x P/B) following a 56.8% one-year decline, attracting deep value investors, distressed debt specialists, or turnaround-focused funds betting on operational restructuring, strategic sale, or asset liquidation value. The improving net income growth (57.9% YoY) despite revenue decline suggests cost-cutting progress that may appeal to activist investors. Not suitable for growth, income, or conservative investors given negative cash flow, operational losses, and high execution risk. Requires high risk tolerance and willingness to underwrite binary outcomes.
high - The stock exhibits extreme volatility with -26.6% three-month and -56.8% one-year returns, typical of micro-cap pharmaceutical companies with operational distress. Volatility driven by binary events (ANDA approvals, earnings surprises, financing announcements) rather than systematic market factors. Low liquidity given near-zero market cap amplifies price swings on modest volume. Implied beta likely exceeds 1.5x based on distressed financial profile and sector positioning.
